Effects of Open-Label, Adjunctive Ganaxolone on Persistent Depression Despite Adequate Antidepressant Treatment in Postmenopausal Women | Zendy

Laura E. Dichtel | Zendy; Maren Nyer | Zendy; Christina Dording | Zendy; Lauren Fisher | Zendy; Cristina Cusin | Zendy; Benjamin G. Shapero | Zendy; Paola Pedrelli | Zendy; Allison Kimball | Zendy; Elizabeth M. Rao | Zendy; David Mischoulon | Zendy; Maurizio Fava | Zendy; Karen K. Miller | Zendy

Open Access

Effects of Open-Label, Adjunctive Ganaxolone on Persistent Depression Despite Adequate Antidepressant Treatment in Postmenopausal Women

Author(s) -

Laura E. Dichtel,

Maren Nyer,

Christina Dording,

Lauren Fisher,

Cristina Cusin,

Benjamin G. Shapero,

Paola Pedrelli,

Allison Kimball,

Elizabeth M. Rao,

David Mischoulon,

Maurizio Fava,

Karen K. Miller

Publication year - 2020

Publication title -

the journal of clinical psychiatry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.677

H-Index - 207

eISSN - 1534-8628

pISSN - 0160-6689

DOI - 10.4088/jcp.19m12887

Subject(s) - allopregnanolone , neuroactive steroid , depression (economics) , major depressive episode , antidepressant , major depressive disorder , medicine , mood , rating scale , psychology , psychiatry , gabaa receptor , receptor , economics , macroeconomics , developmental psychology , hippocampus

The neuroactive steroid metabolite of progesterone, allopregnanolone, is a positive allosteric modulator of γ-aminobutyric acid-A (GABAA) receptors and a putative treatment for mood disorders. This pilot study was performed to determine whether an oral allopregnanolone analog (ganaxolone) may be effective adjunctive therapy for persistent depression despite adequate antidepressant treatment in postmenopausal women.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research